Opioids are produced synthetically or naturally in laboratories to mimic the chemical characteristics of opioids which interact with opioid receptors on nerve cells in the body and brain to relieve pain. They are a group of substances that also includes heroin, synthetic opioids and prescription pain relievers. Prescription opioids are intended to be used to manage acute pain, such as that experienced after an injury or surgery, chronic pain, cancer that is actively being treated, hospice care, and end-of-life care. Many patients under medical care rely on prescription opioids to help them manage their problems. Opioid use disorder is a chronic, lifelong condition with potentially serious consequences, including disability, relapse, and death.
The global opioids use disorder market was estimated at $2.8 billion in 2021 and is expected to hit $8.1 billion by 2031, registering a CAGR of 11.5% from 2022 to 2031. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.
- CAGR: 11.5%
- Current Market Size: USD 2.8 Billion
- Forecast Growing Region: APAC
- Largest Market: North America
- Projection Time: 2021 – 2031
- Base Year: 2021
Download Free Sample Report- https://www.alliedmarketresearch.com/request-sample/12668
Covid-19 scenario-
- A large number of clinics and hospitals around the world have been refurbished to increase hospital capacity for patients diagnosed with Covid-19. Furthermore, the postponement or cancellation of medical appointments has severely affected the global opioid use disorder market. • The decline in the number of scheduled surgeries has led to a decrease in the demand for opioids, which has caused a decrease in the prevalence of opioid use disorder.
The global opioids use disorder market is analyzed across drug type, age group, route of administration, distribution channel, and region. The report takes in an exhaustive analysis of segments and their sub-segments with the help of tabular and graphical representation. Investors and market players can benefit from the breakdown and devise stratagems based on the highest revenue-generating and fastest-growing segments stated in the report.
Based on drug type, the agonist segment contributed to more than four-fifths of the global opioids use disorder market in 2021 and is expected to dominate by 2031. The same segment would also showcase the fastest CAGR of 11.6% throughout the forecast period.
Based on age group, the 19 to 39 segment held nearly half of the total market revenue in 2021 and is expected to dominate by 2031. The same segment would also manifest the fastest CAGR of 11.9% throughout the forecast period.
Based on route of administration, the intravenous segment held around more than half of the total market revenue in 2021 and is expected to dominate by 2031. The same segment would also cite the fastest CAGR of 11.9% throughout the forecast period.
By distribution channel, the hospital pharmacy segment accounted for nearly three-quarters of the total market revenue in 2021 and is expected to dominate by 2031. The same segment would also project the fastest CAGR of 11.6% for the full period of prognosis.
Based on region, the market across North America generated nearly two-fifths of the global opioids use disorder market revenue in 2021 and is anticipated to retain the lion’s share by 2031. Asia-Pacific, on the other hand, would showcase the fastest CAGR of 12.3% during the forecast period. The other regions studied in the report include LAMEA and Europe.
For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/12668
The key market players analyzed in the global opioids use disorder market report include AstraZeneca Plc.,
BioDelivery Sciences International Inc.,
Braeburn,
Cerebral,
Hikma Pharmaceuticals PLC,
NYC Health + Hospitals,
Dr. Reddy,
Indivior PLC,
Mallinckrodt Pharmaceuticals,
Alkermes,
Orexo AB,
Camurus,
Pear Therapeutics,
Pfizer,
Reckitt Benckiser Pharmaceuticals Inc.,
Sandoz (Novartis),
Viatris Inc.,
and Titan Pharmaceuticals, Inc
Know More- https://www.alliedmarketresearch.com/press-release/opioid-use-disorder-market.html